Search results for "GF"

showing 10 items of 838 documents

Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells

2014

Background: In hepatocellular carcinoma (HCC), different signaling pathways are de-regulated, and among them, the expression of the epidermal growth factor receptor (EGFR). Tyrphostin AG-1478 is a lipophilic low molecular weight inhibitor of EGFR, preferentially acting on liver tumor cells. In order to overcome its poor drug solubility and thus improving its anticancer activity, it was entrapped into nanostructured lipid carriers (NLC) by using safe ingredients for parenteral delivery. Results: Nanostructured lipid carriers (NLC) carrying tyrphostin AG-1478 were prepared by using the nanoprecipitation method and different matrix compositions. The best system in terms of mean size, PDI, zeta…

DrugCarcinoma HepatocellularHepatocellular carcinomamedia_common.quotation_subjectBiomedical EngineeringMedicine (miscellaneous)Pharmaceutical ScienceAntineoplastic AgentsBioengineeringPharmacologyApplied Microbiology and BiotechnologyCell Line TumormedicineHumansEpidermal growth factor receptorNanostructured lipid carriers Tyrphostin AG-1478 Drug release Hepatocellular carcinoma EGFR inhibitor.media_commonEGFR inhibitorsDrug CarriersNanostructured lipid carriersbiologyChemistryResearchLiver NeoplasmsCorrectionDrug releaseTyrphostinsmedicine.diseaseLipidsTyrphostin AG-1478Molecular medicineIn vitroNanostructuresErbB ReceptorsEGFR inhibitorLiverSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoHepatocellular carcinomaDrug deliveryQuinazolinesbiology.proteinMolecular MedicineDrug carrier
researchProduct

Gefitinib in lung cancer therapy. Clinical results, predictive markers of response and future perspectives.

2009

Over the past few years, epidermal growth factor receptor has emerged as one of the most important targets in tumorgenesis and several drugs targeting signal transduction pathways have been developed. The first among these agents to be approved for the treatment of NSCLC was gefitinib, a potent, selective and reversible inhibitor of HER1/EGFR tyrosine kinase activity. The review summarizes its clinical development and the new therapeutic options, with particular focus on predictive markers of susceptibility to this drug.

DrugOncologyCancer Researchmedicine.medical_specialtyLung Neoplasmsmolecular markersmedia_common.quotation_subjectgefitinibAntineoplastic AgentsGefitinibcancer therapyGefitinibCarcinoma Non-Small-Cell LungInternal medicinetyrosine kinase inhibitorsmedicineAnimalsHumansgefitinib; non-small cell lung cancer (NSCLC); epidermal growth factor receptor (HER1/EGFR); tyrosine kinase inhibitors; target therapy; molecular markers; EGFR mutationsEpidermal growth factor receptorLung cancermedia_commonPharmacologyClinical Trials as Topicbiologybusiness.industrytarget therapymedicine.diseaseEGFR mutationsepidermal growth factor receptor (HER1/EGFR)ErbB Receptorsnon-small cell lung cancer (NSCLC)OncologyQuinazolinesbiology.proteinMolecular MedicineSignal transductionbusinessBiomarkersEgfr tyrosine kinaseSignal Transductionmedicine.drug
researchProduct

Toward a Rationale for the PTC124 (Ataluren) Promoted Readthrough of Premature Stop Codons: A Computational Approach and GFP-Reporter Cell-Based Assay

2014

The presence in the mRNA of premature stop codons (PTCs) results in protein truncation responsible for several inherited (genetic) diseases. A well-known example of these diseases is cystic fibrosis (CF), where approximately 10% (worldwide) of patients have nonsense mutations in the CF transmembrane regulator (CFTR) gene. PTC124 (3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)-benzoic acid), also known as Ataluren, is a small molecule that has been suggested to allow PTC readthrough even though its target has yet to be identified. In the lack of a general consensus about its mechanism of action, we experimentally tested the ability of PTC124 to promote the readthrough of premature termination c…

Duchenne muscular distrophy (DMD)Protein ConformationNonsense mutationBlotting WesternGreen Fluorescent ProteinsPharmaceutical ScienceCystic Fibrosis Transmembrane Conductance RegulatorSettore BIO/11 - Biologia MolecolareBiologyMolecular Dynamics Simulationmedicine.disease_causeReal-Time Polymerase Chain Reactionpremature termination codons (PTC)ArticleGreen fluorescent proteinchemistry.chemical_compoundDrug DiscoverymedicineCoding regionHumansRNA Messengermolecular dynamics (MD)GeneCells CulturedGeneticsnonsense mutation readthroughMessenger RNAMutationOxadiazolesReverse Transcriptase Polymerase Chain Reactiongreen fluorescent protein (GFP)atalurenSettore CHIM/06 - Chimica OrganicaStop codonAtalurenSettore BIO/18 - GeneticachemistryCodon NonsenseSettore CHIM/03 - Chimica Generale E InorganicaMutationCodon TerminatorMutagenesis Site-DirectedMolecular MedicineNucleic Acid Conformationcystic fibrosis (CF)oxadiazoleHeLa Cells
researchProduct

Négligence illicite et responsabilités multiples: partage ou cumul de responsabilités?

2018

This paper addresses the issue of the distribution of international responsibility between two or more States or between an international organization and its member States in case of violation of obligations of due diligence.

Due diligence international responsibility responsibility of member States of an International Organization Aid or Assistance in the commission of an international wrongful actSettore IUS/13 - Diritto Internazionale
researchProduct

Eisüberlastung in Daugava: Salaspils (11.,13.,17.04.1904.)

1904

K. R. Kupfera 1904. gada aprīlī fotografētie ledus sastrēgumi Daugavā pie Salaspils. K. R. Kupfer's photographed ice jams in Daugava near Salaspils on April 1904, with a autor's description. K. R. Kupfer fotografierte am April 1904 Eisstauungen in der Daugava bei Salaspils Island mit einer Beschreibung vom Autor.

Dünaledus sastrēgumiSalaspilsDaugavaKurtenhofEisüberlastungJungfrauhofJumpravmuiža:NATURAL SCIENCES::Earth sciences [Research Subject Categories]Eissatuungen
researchProduct

EGFL7 ligates αvβ3 integrin to enhance vessel formation

2013

Angiogenesis, defined as blood vessel formation from a preexisting vasculature, is governed by multiple signal cascades including integrin receptors, in particular integrin αVβ3. Here we identify the endothelial cell (EC)-secreted factor epidermal growth factor-like protein 7 (EGFL7) as a novel specific ligand of integrin αVβ3, thus providing mechanistic insight into its proangiogenic actions in vitro and in vivo. Specifically, EGFL7 attaches to the extracellular matrix and by its interaction with integrin αVβ3 increases the motility of EC, which allows EC to move on a sticky underground during vessel remodeling. We provide evidence that the deregulation of EGFL7 in zebrafish embryos leads …

EGF Family of ProteinsEmbryo NonmammalianAngiogenesisAmino Acid MotifsImmunologyIntegrinGene ExpressionMice NudeEndothelial Growth FactorsBiochemistryCollagen receptorMiceCell MovementCell AdhesionHuman Umbilical Vein Endothelial CellsmedicineAnimalsHumansImmunoprecipitationPhosphorylationZebrafishbiologyReverse Transcriptase Polymerase Chain ReactionChemistryCalcium-Binding ProteinsInfarction Middle Cerebral ArteryVenous plexusCell BiologyHematologyIntegrin alphaVbeta3ImmunohistochemistryExtracellular MatrixCell biologyEndothelial stem cellHEK293 Cellsmedicine.anatomical_structureIntegrin alpha MImmunologybiology.proteinBlood VesselsRNA InterferenceIntegrin beta 6Protein BindingBlood vesselBlood
researchProduct

FEASIBILITY OF EGFR EVALUATION IN BLADDER WASHINGS OF PATIENTS AFFECTED BY NON MUSCLE-INVASIVE BLADDER CANCER.

2016

EGF-R bladder cancer
researchProduct

Atomic Structures of Two Novel Immunoglobulin-like Domain Pairs in the Actin Cross-linking Protein Filamin

2009

Filamins are actin filament cross-linking proteins composed of an N-terminal actin-binding domain and 24 immunoglobulin-like domains (IgFLNs). Filamins interact with numerous proteins, including the cytoplasmic domains of plasma membrane signaling and cell adhesion receptors. Thereby filamins mechanically and functionally link the cell membrane to the cytoskeleton. Most of the interactions have been mapped to the C-terminal IgFLNs 16–24. Similarly, as with the previously known compact domain pair of IgFLNa20–21, the two-domain fragments IgFLNa16–17 and IgFLNa18–19 were more compact in small angle x-ray scattering analysis than would be expected for two independent domains. Solution state NM…

EGF-like domainFilaminsMolecular Sequence DataMolecular ConformationImmunoglobulinsmacromolecular substancesPlasma protein bindingBiologyFilaminModels BiologicalBiochemistryCell membraneHAMP domain03 medical and health sciencesContractile Proteins0302 clinical medicineddc:570Cell AdhesionmedicineHumansScattering RadiationAmino Acid SequenceCytoskeletonCell adhesionMolecular BiologyCytoskeletonActin030304 developmental biology0303 health sciencesMicrofilament ProteinsCell BiologyActinsRecombinant ProteinsProtein Structure Tertiary3. Good healthCell biologyCross-Linking Reagentsmedicine.anatomical_structureProtein Structure and Folding030217 neurology & neurosurgeryProtein BindingJournal of Biological Chemistry
researchProduct

A peptide inhibiting the collagen binding function of integrin alpha2I domain.

1999

Integrin alpha2 subunit forms in the complex with the beta1 subunit a cell surface receptor binding extracellular matrix molecules, such as collagens and laminin-1. It is a receptor for echovirus-1, as well. Ligands are recognized by the special "inserted" domain (I domain) in the integrin alpha2 subunit. Venom from a pit viper, Bothrops jararaca, has been shown to inhibit the interaction of platelet alpha2beta1 integrin with collagen because of the action of a disintegrin/metalloproteinase named jararhagin. The finding that crude B. jararaca venom could prevent the binding of human recombinant ralpha2I domain to type I collagen led us to study jararhagin further. Synthetic peptides represe…

EGF-like domainIntegrinIntegrin alpha2PeptideBiologyBiochemistryPeptides CyclicEuropiumAntigens CDCrotalid VenomsDisintegrinHumansAmino Acid SequenceMolecular BiologyRGD motifDNA Primerschemistry.chemical_classificationBase SequenceCell MembraneMetalloendopeptidasesCell BiologyCyclic peptideRecombinant ProteinsBiochemistrychemistryJararhaginbiology.proteinCollagenBinding domainThe Journal of biological chemistry
researchProduct

Crystal structure of human gamma-butyrobetaine hydroxylase.

2010

Gamma-butyrobetaine hydroxylase (GBBH) is a 2-ketoglutarate-dependent dioxygenase that catalyzes the biosynthesis of l-carnitine by hydroxylation of gamma-butyrobetaine (GBB). l-carnitine is required for the transport of long-chain fatty acids into mitochondria for generating metabolic energy. The only known synthetic inhibitor of GBBH is mildronate (3-(2,2,2-trimethylhydrazinium) propionate dihydrate), which is a non-hydroxylatable analog of GBB. To aid in the discovery of novel GBBH inhibitors by rational drug design, we have solved the three-dimensional structure of recombinant human GBBH at 2.0A resolution. The GBBH monomer consists of a catalytic double-stranded beta-helix (DBSH) domai…

EGF-like domainStereochemistrygamma-Butyrobetaine DioxygenaseBiophysicsDrug designBiochemistryHydroxylationchemistry.chemical_compoundDioxygenaseCatalytic DomainHumansEnzyme InhibitorsMolecular BiologyHistidinechemistry.chemical_classificationCrystallographybiologyActive siteCell BiologyRecombinant ProteinsZincEnzymeBiochemistrychemistryCyclic nucleotide-binding domainDrug Designbiology.proteinProtein MultimerizationMethylhydrazinesBiochemical and biophysical research communications
researchProduct